<DOC>
	<DOCNO>NCT00846716</DOCNO>
	<brief_summary>The purpose study investigate whether oral anti-diabetic drug , Thiazolidine ( TZD ) effective suppression onset progressin diabetic nephropathy Japanese type 2 diabetic patient .</brief_summary>
	<brief_title>Shiga Progression Diabetes , Nephropathy Retinopathy</brief_title>
	<detailed_description>2 . Outcome measure : 1 . Primary endpoint Onset progression diabetic nephropathy 2 . Secondary endpoint ( 1 ) Progression diabetes mellitus ( 2 ) Change HbA1c ( 3 ) Change albumin-creatinine ratio ( 4 ) Change GFR ( 5 ) CHange cystatin C</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Less 8.0 % HbA1c Less 300 mg/g Cr urinary albumine level Concomitant therapy SU and/or Biguanide Untreated hypertension hypertension treat ARB ACEI History heart failure concomitant heart failure History administration TZD agent Severe hepatic dysfunction 3 time high upper limit normal range GOT , GPT rGPT Severe renal dysfunction 2.5 Cr History AE TZD agent Insulin treatment Concomitant urinary track infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>pioglitazone</keyword>
</DOC>